Vivanza Biosci.

how big is Vivanza Biosci.?

As of Jun 06, Vivanza Biosciences Ltd has a market capitalization of 10.00 Cr, with recent net sales of 7.42 Cr and a net profit of -0.67 Cr over the last four quarters. Shareholder's funds are 4.64 Cr, and total assets amount to 19.50 Cr as of Mar'24.

Market Cap: As of Jun 06, Vivanza Biosciences Ltd has a market capitalization of 10.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes data from Mar'25, Dec'24, Sep'24, and Jun'24, is 7.42 Cr. The sum of Net Profit for the same quarters is -0.67 Cr. This data is presented on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is also on a Consolidated basis for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 4.64 Cr, while Total Assets amount to 19.50 Cr.

What does Vivanza Biosci. do?

Vivanza Biosciences Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, focusing on providing quality pharmaceutical products globally. Established in 1982, it reported net sales of 0 Cr and a net profit of -1 Cr for the quarter ending March 2025.

Overview:<BR>Vivanza Biosciences Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company, focusing on providing global quality pharmaceutical products at competitive prices.<BR><BR>History:<BR>Vivanza Biosciences Ltd was established in March 1982 and was initially known as Ivee Injectaa Limited. It transitioned from a Private Limited Company to a Public Limited Company in May 1992. The company rebranded and came into existence as Vivanza Biosciences in April 2016. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 10 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 32 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 2.15 <BR>Return on Equity: -16.92% <BR>Price to Book: 2.43<BR><BR>Contact Details:<BR>Address: 403 Sarthik 2 Opp Rajpath Club, S G Highway Ahmedabad Gujarat : 380054 <BR>Tel: 91-07405699869 <BR>Website: http://www.vivanzabiosciences.com

Who are in the management team of Vivanza Biosci.?

As of March 2022, the management team of Vivanza Biosci includes Hemant Parikh (Director), Sunil Shah (Independent Director), Avinash G. Bhojwani (Company Secretary & Compliance Officer), Apeksha Vyas (Independent Director), and Jayendra Mehta (Managing Director). Avinash G. Bhojwani is the only member receiving remuneration, amounting to Rs. 4.57 lacs.

As of March 2022, the management team of Vivanza Biosci includes the following individuals:<BR><BR>1. Hemant Parikh - Director<BR>2. Sunil Shah - Independent Director<BR>3. Avinash G. Bhojwani - Company Secretary & Compliance Officer<BR>4. Apeksha Vyas - Independent Director<BR>5. Jayendra Mehta - Managing Director<BR><BR>Avinash G. Bhojwani is the only member of the management team receiving remuneration, which is Rs. 4.57 lacs.

Has Vivanza Biosci. declared dividend?

No Dividend History Available

Who are the peers of the Vivanza Biosci.?

Vivanza Biosci.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab. While Sun Pharma, Cipla, and Dr Reddy's Labs show excellent management and growth, Vivanza Biosci. has below average performance with a 1-year return of -60.94%.

Peers: The peers of Vivanza Biosci. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest have below average management risk. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is found at Vivanza Biosci., Divi's Lab., Torrent Pharma, Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, whereas below average capital structure is present at Vivanza Biosci., Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while Cian Healthcare has the lowest at -82.59%. Vivanza Biosci.'s 1-year return is -60.94%, which is significantly lower than Divi's Lab. and higher than Cian Healthcare. Additionally, the six-month return is negative for Vivanza Biosci., Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab.

Is Vivanza Biosci. overvalued or undervalued?

As of May 13, 2025, Vivanza Biosci. is considered risky and overvalued due to a negative PE ratio of -9.52, an EV to EBIT of -18.05, and a ROE of -16.92%, significantly underperforming compared to its peers, with a 59.33% decline in stock performance over the past year.

As of 13 May 2025, the valuation grade for Vivanza Biosci. has moved from attractive to risky, indicating a significant shift in the company's perceived value. The company is currently considered overvalued, given its negative PE ratio of -9.52 and an EV to EBIT of -18.05, which highlight underlying financial distress. Additionally, the ROE stands at -16.92%, further emphasizing the challenges faced by the company.<BR><BR>In comparison to its peers, Vivanza Biosci. lags significantly behind. For instance, Altius Telecom, rated very attractive, boasts a PE ratio of 52.97, while other peers like Embassy Office REIT and Inventurus Knowledge are categorized as very expensive with PE ratios of 23.06 and 56.63, respectively. The stark contrast in these ratios suggests that Vivanza Biosci. is not only underperforming but also carries a higher risk profile relative to its industry counterparts. Recent stock performance shows a decline of 59.33% over the past year, contrasting sharply with the Sensex's return of 7.65%, reinforcing the notion of overvaluation.

What is the technical trend for Vivanza Biosci.?

As of June 4, 2025, Vivanza Biosci's trend has shifted to mildly bearish, indicated by daily moving averages and weekly RSI, despite a mildly bullish weekly MACD, with overall indicators suggesting weakness and significant underperformance over the past year.

As of 4 June 2025, the technical trend for Vivanza Biosci has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly RSI showing bearish momentum. Although the weekly MACD is mildly bullish, the overall indicators, including the Bollinger Bands and KST on a monthly basis, suggest weakness. The Dow Theory indicates no clear trend in both weekly and monthly perspectives. The stock has underperformed significantly over the past year, further supporting the bearish outlook.

Who are the top shareholders of the Vivanza Biosci.?

The top shareholders of Vivanza Biosci are Parth Hemant Parikh with 19.77%, Ashoka Metcast Limited with 3.85%, and individual investors who collectively own 73.69%. There are no institutional investors or mutual funds involved.

The top shareholders of Vivanza Biosci include Parth Hemant Parikh, who holds the highest stake at 19.77%. The next significant public shareholder is Ashoka Metcast Limited, with a holding of 3.85%. Additionally, individual investors collectively hold a substantial 73.69% of the company's shares. There are no institutional investors or mutual funds involved in the shareholding.

How has been the historical performance of Vivanza Biosci.?

Vivanza Biosci. experienced significant financial declines, reporting net sales of 7.42 Cr in March 2025, down from 27.84 Cr in March 2024, resulting in a loss with a profit after tax of -0.67 Cr. The company faced negative cash flow and decreased total assets and liabilities during this period.

Answer:<BR>The historical performance of Vivanza Biosci. shows significant fluctuations in its financial metrics over the years, culminating in a loss in the most recent fiscal year.<BR><BR>Breakdown:<BR>Vivanza Biosci. reported net sales of 7.42 Cr in March 2025, a sharp decline from 27.84 Cr in March 2024 and 17.81 Cr in March 2023. The total operating income mirrored this trend, dropping to 7.42 Cr in March 2025 from 27.84 Cr in the previous year. Total expenditure also decreased to 7.79 Cr in March 2025 from 26.77 Cr in March 2024. Operating profit (PBDIT) turned negative at -0.31 Cr in March 2025, following a profit of 1.12 Cr in March 2024. Consequently, the profit before tax fell to -0.67 Cr in March 2025, down from 0.70 Cr in March 2024, leading to a profit after tax of -0.67 Cr compared to a profit of 0.55 Cr in the prior year. The company's total liabilities decreased to 16.45 Cr in March 2025 from 19.50 Cr in March 2024, while total assets also fell to 16.45 Cr from 19.50 Cr. Cash flow from operating activities was negative at -2.00 Cr in March 2025, contrasting with a positive cash flow of 2.00 Cr in March 2024. Overall, the financial performance indicates a challenging year for Vivanza Biosci., marked by declining revenues and profitability.

When is the next results date for Vivanza Biosciences Ltd?

The next results date for Vivanza Biosciences Ltd is 12 February 2026.

The next results date for Vivanza Biosciences Ltd is scheduled for 12 February 2026.

Are Vivanza Biosciences Ltd latest results good or bad?

Vivanza Biosciences Ltd's latest results show impressive year-on-year sales growth of 2916.67% to ₹45.25 crores, but a concerning 18.26% decline from the previous quarter and a low operating margin of 0.46%, raising questions about profitability and sustainability. Overall, the results are mixed, with significant concerns regarding financial health.

Vivanza Biosciences Ltd's latest results present a mixed picture. On one hand, the company reported an impressive year-on-year growth in net sales of 2916.67%, reaching ₹45.25 crores in Q3 FY26. This indicates a significant expansion in revenue compared to the previous year, when net sales were just ₹1.50 crores. However, this growth comes with a downside, as there was an 18.26% decline in sales compared to the previous quarter.<BR><BR>Profitability remains a critical concern. The net profit for Q3 FY26 was ₹0.20 crores, which, while showing a remarkable 400% increase year-on-year, reflects a substantial 64.29% decrease from the previous quarter. The operating margin is extremely low at 0.46%, indicating that the company is facing significant challenges in converting its revenue growth into meaningful profits.<BR><BR>Overall, while the explosive growth in sales is noteworthy, the substantial decline in profitability and the thin operating margins raise serious questions about the sustainability of this growth and the company's overall financial health. Thus, the results can be characterized as concerning, particularly regarding profitability and operational stability.

Should I buy, sell or hold Vivanza Biosciences Ltd?

Which are the latest news on Vivanza Biosci.?

Why is Vivanza Biosciences Ltd falling/rising?

As of 13-Mar, Vivanza Biosciences Ltd's stock price is Rs 1.95, reflecting a 1.52% decrease and a total decline of 3.47% over the last three days. The stock is underperforming the market, trading below key moving averages, and is close to its 52-week low, indicating a bearish trend and diminished investor confidence.

As of 13-Mar, Vivanza Biosciences Ltd's stock price is falling, currently at Rs 1.95, which reflects a decrease of Rs 0.03 or 1.52%. The stock has been on a downward trend, having lost value for the last three consecutive days, resulting in a total decline of 3.47% during this period. Additionally, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend.<BR><BR>In terms of performance relative to the broader market, the stock has underperformed over various time frames, with a year-to-date decline of 11.36%, while the benchmark Sensex has decreased by 12.50%. Furthermore, the stock is close to its 52-week low, being only 2.56% away from Rs 1.90. <BR><BR>Investor participation has also diminished, as evidenced by a significant drop in delivery volume, which fell by 74.87% compared to the 5-day average. This reduction in trading activity suggests a lack of confidence among investors. Overall, these factors contribute to the ongoing decline in Vivanza Biosciences Ltd's stock price.

Why is Vivanza Biosciences Ltd falling/rising?

As of 14-Mar, Vivanza Biosciences Ltd's stock price is Rs 1.95, reflecting a decline of -1.52% and a total drop of -3.47% over the last three days. The stock has underperformed against the market, showing weak long-term fundamentals and is classified as a strong sell.

As of 14-Mar, Vivanza Biosciences Ltd is experiencing a decline in its stock price, currently at Rs 1.95, which reflects a change of -0.03 or -1.52%. The stock has been on a downward trend, having fallen consecutively for the last three days, resulting in a total drop of -3.47% during this period. <BR><BR>In terms of performance relative to the market, the stock has underperformed significantly over various time frames. Over the past week, it has decreased by -1.02%, while the benchmark Sensex has fallen by -5.52%. Over the past month, the stock is down -9.30%, slightly better than the Sensex's -9.76%. Year-to-date, Vivanza's decline stands at -11.36%, compared to the Sensex's -12.50%. However, the stock has shown a stark contrast over the past year, where it has generated a return of -9.30%, while the Sensex has gained +1.00%.<BR><BR>The stock is also trading lower than its moving averages across multiple time frames, indicating a bearish trend. Additionally, there has been a notable decrease in investor participation, with delivery volume dropping by -74.87% against the five-day average, suggesting reduced interest from investors.<BR><BR>Despite some positive financial results, such as a significant increase in net sales and a higher profit after tax, the overall long-term fundamentals appear weak. The company has a high debt-to-EBITDA ratio of 5.05 times, indicating challenges in servicing its debt, and a negative compound annual growth rate (CAGR) of -4.85% in operating profits over the last five years. This consistent underperformance against benchmarks and the weak long-term outlook contribute to the stock's decline, leading to its classification as a strong sell.

Why is Vivanza Biosciences Ltd falling/rising?

As of 15-Mar, Vivanza Biosciences Ltd's stock price is Rs 1.95, down 1.52%, continuing a downward trend with a total decline of 3.47% over the last three days. The stock underperforms against market indices and faces weak fundamentals, leading to diminished investor confidence and trading activity.

As of 15-Mar, Vivanza Biosciences Ltd's stock price is falling, currently at Rs 1.95, reflecting a decrease of Rs 0.03 or 1.52%. The stock has been on a downward trend, having lost value for the last three consecutive days, resulting in a total decline of 3.47% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent weakness in its price performance.<BR><BR>In terms of broader market performance, the stock has underperformed against the benchmark indices, with a year-to-date decline of 11.36% compared to a 12.50% drop in the Sensex. Over the past year, while the stock has generated a return of -9.30%, it has consistently lagged behind the BSE500, showing a pattern of underperformance over the last three years.<BR><BR>Investor participation has also diminished, as evidenced by a significant drop in delivery volume, which fell by 74.87% against the 5-day average. This decline in trading activity suggests a lack of confidence among investors. Furthermore, the company faces challenges with weak long-term fundamentals, including a high Debt to EBITDA ratio of 5.05 times and a negative compound annual growth rate (CAGR) of -4.85% in operating profits over the last five years.<BR><BR>Despite some positive financial results, such as higher net sales and profit after tax in the latest six months, the overall outlook remains negative due to the company's inability to generate consistent returns and its significant underperformance relative to the market.